Search

Your search keyword '"Spellman, Stephen R."' showing total 1,136 results
Start Over Author "Spellman, Stephen R."
1,136 results on '"Spellman, Stephen R."'

1. Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry

Author

Schonfeld, Sara J, Valcarcel, Bryan, Meyer, Christa L, Shaw, Bronwen E, Phelan, Rachel, Rizzo, J Douglas, Brunson, Ann, Cooley, Julianne JP, Abrahão, Renata, Wun, Ted, Gadalla, Shahinaz M, Engels, Eric, Albert, Paul S, Yusuf, Rafeek, Spellman, Stephen R, Curtis, Rochelle E, Auletta, Jeffery J, Muffly, Lori, Keegan, Theresa HM, and Morton, Lindsay M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, HIV/AIDS, Sexually Transmitted Infections, Hematology, Cancer, Minority Health, Transplantation, Clinical Research, Infectious Diseases, Humans, Registries, Hematopoietic Stem Cell Transplantation, California, Incidence, Female, Male, Middle Aged, Neoplasms, Adult, Aged, Adolescent, Young Adult, Child, Cardiovascular medicine and haematology
Abstract

AbstractCompared with the general population, hematopoietic cell transplantation (HCT) survivors are at elevated risk for developing solid subsequent neoplasms (SNs). The Center for International Blood and Marrow Transplant Research (CIBMTR) is a key resource for quantifying solid SN incidence following HCT, but the completeness of SN ascertainment is uncertain. Within a cohort of 18 450 CIBMTR patients linked to the California Cancer Registry (CCR), we evaluated the completeness of solid SN data reported to the CIBMTR from 1991 to 2018 to understand the implications of using CIBMTR data alone or combined with CCR data to quantify the burden of solid SNs after HCT. We estimated the cumulative incidence of developing a solid SN, accounting for the competing risk of death. Within the cohort, solid SNs were reported among 724 patients; 15.6% of these patients had an SN reported by CIBMTR only, 36.9% by CCR only, and 47.5% by both. The corresponding cumulative incidence of developing a solid SN at 10 years following a first HCT was 4.0% (95% confidence interval [CI], 3.5-4.4) according to CIBMTR data only, 5.3% (95% CI, 4.9-5.9) according to CCR data only, and 6.3% (95% CI, 5.7-6.8) according to both sources combined. The patterns were similar for allogeneic and autologous HCT recipients. Linking detailed HCT information from CIBMTR with comprehensive SN data from cancer registries provides an opportunity to optimize SN ascertainment for informing follow-up care practices and evaluating risk factors in the growing population of HCT survivors.

Published
2024

3. Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

Author

Gui, Gege, Ravindra, Niveditha, Hegde, Pranay S., Andrew, Georgia, Mukherjee, Devdeep, Wong, Zoë, Auletta, Jeffery J., El Chaer, Firas, Chen, Evan C., Chen, Yi-Bin, Corner, Adam, Devine, Steven M., Iyer, Sunil G., Jimenez Jimenez, Antonio Martin, De Lima, Marcos J. G., Litzow, Mark R., Kebriaei, Partow, Saber, Wael, Spellman, Stephen R., Zeger, Scott L., Page, Kristin M., Dillon, Laura W., and Hourigan, Christopher S.

Published
2024
Full Text
View/download PDF

5. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection

Author

Augusto, Danillo G, Murdolo, Lawton D, Chatzileontiadou, Demetra SM, Sabatino, Joseph J, Yusufali, Tasneem, Peyser, Noah D, Butcher, Xochitl, Kizer, Kerry, Guthrie, Karoline, Murray, Victoria W, Pae, Vivian, Sarvadhavabhatla, Sannidhi, Beltran, Fiona, Gill, Gurjot S, Lynch, Kara L, Yun, Cassandra, Maguire, Colin T, Peluso, Michael J, Hoh, Rebecca, Henrich, Timothy J, Deeks, Steven G, Davidson, Michelle, Lu, Scott, Goldberg, Sarah A, Kelly, J Daniel, Martin, Jeffrey N, Vierra-Green, Cynthia A, Spellman, Stephen R, Langton, David J, Dewar-Oldis, Michael J, Smith, Corey, Barnard, Peter J, Lee, Sulggi, Marcus, Gregory M, Olgin, Jeffrey E, Pletcher, Mark J, Maiers, Martin, Gras, Stephanie, and Hollenbach, Jill A

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Emerging Infectious Diseases, Vaccine Related, Clinical Research, Pneumonia, Biodefense, Lung, Pneumonia & Influenza, Infectious Diseases, Prevention, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Humans, Alleles, Asymptomatic Infections, COVID-19, Epitopes, T-Lymphocyte, Peptides, SARS-CoV-2, HLA-B Antigens, Cohort Studies, T-Lymphocytes, Immunodominant Epitopes, Cross Reactions, Spike Glycoprotein, Coronavirus, General Science & Technology
Abstract

Studies have demonstrated that at least 20% of individuals infected with SARS-CoV-2 remain asymptomatic1-4. Although most global efforts have focused on severe illness in COVID-19, examining asymptomatic infection provides a unique opportunity to consider early immunological features that promote rapid viral clearance. Here, postulating that variation in the human leukocyte antigen (HLA) loci may underly processes mediating asymptomatic infection, we enrolled 29,947 individuals, for whom high-resolution HLA genotyping data were available, in a smartphone-based study designed to track COVID-19 symptoms and outcomes. Our discovery cohort (n = 1,428) comprised unvaccinated individuals who reported a positive test result for SARS-CoV-2. We tested for association of five HLA loci with disease course and identified a strong association between HLA-B*15:01 and asymptomatic infection, observed in two independent cohorts. Suggesting that this genetic association is due to pre-existing T cell immunity, we show that T cells from pre-pandemic samples from individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF. The majority of the reactive T cells displayed a memory phenotype, were highly polyfunctional and were cross-reactive to a peptide derived from seasonal coronaviruses. The crystal structure of HLA-B*15:01-peptide complexes demonstrates that the peptides NQKLIANQF and NQKLIANAF (from OC43-CoV and HKU1-CoV) share a similar ability to be stabilized and presented by HLA-B*15:01. Finally, we show that the structural similarity of the peptides underpins T cell cross-reactivity of high-affinity public T cell receptors, providing the molecular basis for HLA-B*15:01-mediated pre-existing immunity.

Published
2023

8. Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis

Author

Farhadfar, Nosha, Rashid, Nahid, Chen, Karen, DeVos, Jakob, Wang, Tao, Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Hamilton, Betty K., Hematti, Peiman, Gadalla, Shahinaz M., Solomon, Scott R., El Jurdi, Najla, Lee, Catherine J., MacMillan, Margaret L., Rangarajan, Hemalatha G., Schoemans, Hélène, Sharma, Akshay, Spellman, Stephen R., Wingard, John R., and Lee, Stephanie J.

Published
2024
Full Text
View/download PDF

12. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

Author

Fein, Joshua A., Shouval, Roni, Krieger, Elizabeth, Spellman, Stephen R., Wang, Tao, Baldauf, Henning, Fleischhauer, Katharina, Kröger, Nicolaus, Horowitz, Mary, Maiers, Martin, Miller, Jeffrey S, Mohty, Mohamad, Nagler, Arnon, Weisdorf, Daniel, Malmberg, Karl-Johan, Toor, Amir A., Schetelig, Johannes, Romee, Rizwan, and Koreth, John

Published
2024
Full Text
View/download PDF

14. Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation

Author

Mayor, Neema P, Wang, Tao, Lee, Stephanie J, Kuxhausen, Michelle, Vierra-Green, Cynthia, Barker, Dominic J, Auletta, Jeffrey, Bhatt, Vijaya R, Gadalla, Shahinaz M, Gragert, Loren, Inamoto, Yoshihiro, Morris, Gerald P, Paczesny, Sophie, Reshef, Ran, Ringdén, Olle, Shaw, Bronwen E, Shaw, Peter, Spellman, Stephen R, and Marsh, Steven GE

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Transplantation, Hematology, 2.1 Biological and endogenous factors, Aetiology, Adolescent, Adult, Child, Child, Preschool, Female, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Infant, Infant, Newborn, Male, Transplantation Conditioning, Unrelated Donors, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeUltrahigh resolution (UHR) HLA matching is reported to result in better outcomes following unrelated donor hematopoietic cell transplantation, improving survival and reducing post-transplant complications. However, most studies included relatively small numbers of patients. Here we report the findings from a large, multicenter validation study.MethodsUHR HLA typing was available on 5,140 conventionally 10 out of 10 HLA-matched patients with malignant disease transplanted between 2008 and 2017.ResultsAfter UHR HLA typing, 82% of pairs remained 10 out of 10 UHR-matched; 12.3% of patients were 12 out of 12 UHR HLA-matched. Compared with 12 out of 12 UHR-matched patients, probabilities of grade 2-4 acute graft-versus-host disease (aGVHD) were significantly increased with UHR mismatches (overall P = .0019) and in those patients who were HLA-DPB1 T-cell epitope permissively mismatched or nonpermissively mismatched (overall P = .0011). In the T-cell-depleted subset, the degree of UHR HLA mismatch was only associated with increased transplant-related mortality (TRM) (overall P = .0068). In the T-cell-replete subset, UHR HLA matching was associated with a lower probability of aGVHD (overall P = .0020); 12 out of 12 UHR matching was associated with reduced TRM risk when compared with HLA-DPB1 T-cell epitope permissively mismatched patients, whereas nonpermissive mismatching resulted in a greater risk (overall P = .0003).ConclusionThis study did not confirm that UHR 12 out of 12 HLA matching increases the probability of overall survival but does demonstrate that aGVHD risk, and in certain settings TRM, is lowest in UHR HLA-matched pairs and thus warrants consideration when multiple 10 out of 10 HLA-matched donors of equivalent age are available.

Published
2021

15. National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Author

Shaw, Bronwen E, Jimenez-Jimenez, Antonio Martin, Burns, Linda J, Logan, Brent R, Khimani, Farhad, Shaffer, Brian C, Shah, Nirav N, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John M, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy M, Choe, Hannah, Ambinder, Richard F, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen R, Howard, Alan, Komanduri, Krishna V, Luznik, Leo, Norkin, Maxim, Pidala, Joseph A, Ratanatharathorn, Voravit, Confer, Dennis L, Devine, Steven M, Horowitz, Mary M, and Bolaños-Meade, Javier

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Immunology, Transplantation, Clinical Trials and Supportive Activities, Hematology, Rare Diseases, Clinical Research, Regenerative Medicine, Good Health and Well Being, Adolescent, Adult, Aged, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphoma, Male, Medically Underserved Area, Middle Aged, Minority Groups, Myelodysplastic Syndromes, Prospective Studies, Registries, Transplantation Conditioning, Unrelated Donors, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeHematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.Patients and methodsWe performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning-based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy.ResultsNotably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS.ConclusionOur prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.

Published
2021

16. Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01.

Author

Guethlein, Lisbeth A, Beyzaie, Niassan, Nemat-Gorgani, Neda, Wang, Tao, Ramesh, Vidhyalakshmi, Marin, Wesley M, Hollenbach, Jill A, Schetelig, Johannes, Spellman, Stephen R, Marsh, Steven GE, Cooley, Sarah, Weisdorf, Daniel J, Norman, Paul J, Miller, Jeffrey S, and Parham, Peter

Subjects
Cancer, Rare Diseases, Hematology, Transplantation, Genetics, Genotype, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Receptors, KIR, Recurrence, Immunology
Abstract

In the treatment of acute myelogenous leukemia with allogeneic hematopoietic cell transplantation, we previously demonstrated that there is a greater protection from relapse of leukemia when the hematopoietic cell transplantation donor has either the Cen B/B KIR genotype or a genotype having two or more KIR B gene segments. In those earlier analyses, KIR genotyping could only be assessed at the low resolution of gene presence or absence. To give the analysis greater depth, we developed high-resolution KIR sequence-based typing that defines all the KIR alleles and distinguishes the expressed alleles from those that are not expressed. We now describe and analyze high-resolution KIR genotypes for 890 donors of this human transplant cohort. Cen B01 and Cen B02 are the common CenB haplotypes, with Cen B02 having evolved from Cen B01 by deletion of the KIR2DL5, 2DS3/5, 2DP1, and 2DL1 genes. We observed a consistent trend for Cen B02 to provide stronger protection against relapse than Cen B01 This correlation indicates that protection depends on the donor having inhibitory KIR2DL2 and/or activating KIR2DS2, and is enhanced by the donor lacking inhibitory KIR2DL1, 2DL3, and 3DL1. High-resolution KIR typing has allowed us to compare the strength of the interactions between the recipient's HLA class I and the KIR expressed by the donor-derived NK cells and T cells, but no clinically significant interactions were observed. The trend observed between donor Cen B02 and reduced relapse of leukemia points to the value of studying ever larger transplant cohorts.

Published
2021

20. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT

Author

Olsen, Kelly S., Jadi, Othmane, Dexheimer, Sarah, Bortone, Dante S., Vensko, Steven P., II, Bennett, Sarah, Tang, Hancong, Diiorio, Marisa, Saran, Tanvi, Dingfelder, David, Zhu, Qianqian, Wang, Yiwen, Haiman, Christopher A., Pooler, Loreall, Sheng, Xin, Webb, Amy, Pasquini, Marcelo C., McCarthy, Philip L., Spellman, Stephen R., Weimer, Eric, Hahn, Theresa, Sucheston-Campbell, Lara, Armistead, Paul M., and Vincent, Benjamin G.

Published
2023
Full Text
View/download PDF

24. Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry

Author

Cusatis, Rachel, Litovich, Carlos, Feng, Zhongyu, Allbee-Johnson, Mariam, Kapfhammer, Miranda, Mattila, Deborah, Akinola, Idayat, Phelan, Rachel, Broglie, Larisa, Auletta, Jeffery J., Steinert, Patricia, Bolon, Yung-Tsi, Akhtar, Othman, Bloomquist, Jenni, Chen, Min, Devine, Steven M., Bupp, Caitrin, Hamadani, Mehdi, Hengen, Mary, Jaglowski, Samantha, Kaur, Manmeet, Kuxhausen, Michelle, Lee, Stephanie J., Moskop, Amy, Page, Kristin M., Pasquini, Marcelo C., Rizzo, Doug, Saber, Wael, Spellman, Stephen R., Stefanski, Heather E., Tuschl, Eileen, Yusuf, Rafeek, Zhan, Keming, Flynn, Kathryn E., and Shaw, Bronwen E.

Published
2024
Full Text
View/download PDF

25. Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient Outcomes

Author

Bolon, Yung-Tsi, Atshan, Rasha, Allbee-Johnson, Mariam, Estrada-Merly, Noel, Auletta, Jeffery J., Broglie, Larisa, Cusatis, Rachel, Page, Kristin M., Phelan, Rachel, Sajulga, Ray, Jr., Shaw, Bronwen E., Spahn, Ashley, Steinert, Patricia, Stewart, Valerie, Vierra-Green, Cynthia, Lee, Stephanie J., and Spellman, Stephen R.

Published
2024
Full Text
View/download PDF

26. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.

Author

Al Malki, Monzr M., primary, Bo-Subait, Stephanie, additional, Logan, Brent, additional, Olson, Janelle, additional, Leckrone, Erin, additional, Wu, Juan, additional, Stefanski, Heather E., additional, Auletta, Jeffery J., additional, Spellman, Stephen R., additional, Malmberg, Craig, additional, Shaffer, Brian C., additional, Modi, Dipenkumar, additional, Khimani, Farhad, additional, Gooptu, Mahasweta, additional, Hamadani, Mehdi, additional, Broglie, Larisa, additional, Shaw, Bronwen E., additional, Devine, Steven Michael, additional, and Jimenez Jimenez, Antonio Martin, additional

Published
2024
Full Text
View/download PDF

28. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis

Author

Saliba, Rima M., Alousi, Amin M., Pidala, Joseph, Arora, Mukta, Spellman, Stephen R., Hemmer, Michael T., Wang, Tao, Abboud, Camille, Ahmed, Sairah, Antin, Joseph H., Beitinjaneh, Amer, Buchbinder, David, Byrne, Michael, Cahn, Jean-Yves, Choe, Hannah, Hanna, Rabi, Hematti, Peiman, Kamble, Rammurti T., Kitko, Carrie L., Laughlin, Mary, Lekakis, Lazaros, MacMillan, Margaret L., Martino, Rodrigo, Mehta, Parinda A., Nishihori, Taiga, Patel, Sagar S., Perales, Miguel-Angel, Rangarajan, Hemalatha G., Ringdén, Olov, Rosenthal, Joseph, Savani, Bipin N., Schultz, Kirk R., Seo, Sachiko, Teshima, Takanori, van der Poel, Marjolein, Verdonck, Leo F., Weisdorf, Daniel, Wirk, Baldeep, Yared, Jean A., Schriber, Jeffrey, Champlin, Richard E., and Ciurea, Stefan O.

Published
2022
Full Text
View/download PDF

30. Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes

Author

McReynolds, Lisa J., Rafati, Maryam, Wang, Youjin, Ballew, Bari J., Kim, Jung, Williams, Valencia V., Zhou, Weiyin, Hendricks, Rachel M., Dagnall, Casey, Freedman, Neal D., Carter, Brian, Strollo, Sara, Hicks, Belynda, Zhu, Bin, Jones, Kristine, Paczesny, Sophie, Marsh, Steven G.E., Spellman, Stephen R., He, Meilun, Wang, Tao, Lee, Stephanie J., Savage, Sharon A., and Gadalla, Shahinaz M.

Published
2022
Full Text
View/download PDF

31. Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis

Author

Brown, Derek W., Zhou, Weiyin, Wang, Youjin, Jones, Kristine, Luo, Wen, Dagnall, Casey, Teshome, Kedest, Klein, Alyssa, Zhang, Tongwu, Lin, Shu-Hong, Lee, Olivia W., Khan, Sairah, Vo, Jacqueline B., Hutchinson, Amy, Liu, Jia, Wang, Jiahui, Zhu, Bin, Hicks, Belynda, Martin, Andrew St., Spellman, Stephen R., Wang, Tao, Deeg, H. Joachim, Gupta, Vikas, Lee, Stephanie J., Freedman, Neal D., Yeager, Meredith, Chanock, Stephen J., Savage, Sharon A., Saber, Wael, Gadalla, Shahinaz M., and Machiela, Mitchell J.

Published
2022
Full Text
View/download PDF

34. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Author

Fuchs, Ephraim J., McCurdy, Shannon R., Solomon, Scott R., Wang, Tao, Herr, Megan R., Modi, Dipenkumar, Grunwald, Michael R., Nishihori, Taiga, Kuxhausen, Michelle, Fingerson, Stephanie, McKallor, Caroline, Bashey, Asad, Kasamon, Yvette L., Bolon, Yung-Tsi, Saad, Ayman, McGuirk, Joseph, Paczesny, Sophie, Gadalla, Shahinaz M., Marsh, Steven G.E., Shaw, Bronwen E., Spellman, Stephen R., Lee, Stephanie J., and Petersdorf, Effie W.

Published
2022
Full Text
View/download PDF

35. Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.

Author

Shaffer, Brian C., Gooptu, Mahasweta, DeFor, Todd E., Maiers, Martin, Bolaños-Meade, Javier, Abboud, Ramzi, Briggs, Adrienne D., Khimani, Farhad, Modi, Dipenkumar, Newcomb, Richard, Shpall, Elizabeth J., Bupp, Caitrin, Spellman, Stephen R., Stefanski, Heather E., Shaw, Bronwen E., Auletta, Jeffery J., Devine, Steven M., Jimenez Jimenez, Antonio M., and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

36. Telomere length and clonal chromosomal alterations in peripheral blood of patients with severe aplastic anaemia.

Author

Strauss, Joshua D., Brown, Derek W., Zhou, Weiyin, Dagnall, Casey, Yuan, Jian‐Min, Im, Annie, Savage, Sharon A., Wang, Youjin, Rafati, Maryam, Spellman, Stephen R., and Gadalla, Shahinaz M.

Subjects
APLASTIC anemia, BONE marrow, TREATMENT effectiveness, WOMEN patients, TELOMERES
Abstract

Summary: Severe aplastic anaemia (SAA) is a rare and life‐threatening bone marrow failure disorder. We used data from the transplant outcomes in aplastic anaemia study to characterize mosaic chromosomal alterations (mCAs) in the peripheral blood of 738 patients with acquired SAA and evaluate their associations with telomere length (TL) and survival post‐haematopoietic cell transplant (HCT). The median age at HCT was 20.4 years (range = 0.2–77.4). Patients with SAA had shorter TL than expected for their age (median TL percentile for age: 35.7th; range <1–99.99). mCAs were detected in 211 patients (28.6%), with chr6p copy‐neutral loss of heterozygosity (6p‐CNLOH) in 15.9% and chr7 loss in 3.0% of the patients; chrX loss was detected in 4.1% of female patients. Negative correlations between mCA cell fraction and measured TL (r = −0.14, p = 0.0002), and possibly genetically predicted TL (r = −0.07, p = 0.06) were noted. The post‐HCT 3‐year survival probability was low in patients with chr7 loss (39% vs. 72% in patients with chr6‐CNLOH, 60% in patients with other mCAs and 70% in patients with no mCAs; p‐log rank = 0.001). In multivariable analysis, short TL (p = 0.01), but not chr7 loss (p = 0.29), was associated with worse post‐HCT survival. TL may guide clinical decisions in patients with SAA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

Author

Bhatt, Vijaya Raj, Wang, Tao, Chen, Karen, Kitko, Carrie L., MacMillan, Margaret L., Pidala, Joseph A., Al Malki, Monzr M., Badawy, Sherif M., Beitinjaneh, Amer, Ganguly, Siddhartha, Hamilton, Betty, Hildebrandt, Gerhard C., Lekakis, Lazaros J., Liu, Hongtao, Maziarz, Richard T., Modi, Dipenkumar, Murthy, Hemant S., Preussler, Jaime M., Sharma, Akshay, Spellman, Stephen R., Arora, Mukta, and Lee, Stephanie J.

Published
2022
Full Text
View/download PDF

38. Donor whole blood DNA methylation is not a strong predictor of acute graft versus host disease in unrelated donor allogeneic haematopoietic cell transplantation

Author

Webster, Amy P., primary, Ecker, Simone, additional, Moghul, Ismail, additional, Liu, Xiaohong, additional, Dhami, Pawan, additional, Marzi, Sarah, additional, Paul, Dirk S., additional, Kuxhausen, Michelle, additional, Lee, Stephanie J., additional, Spellman, Stephen R., additional, Wang, Tao, additional, Feber, Andrew, additional, Rakyan, Vardhman, additional, Peggs, Karl S., additional, and Beck, Stephan, additional

Published
2024
Full Text
View/download PDF

39. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight

Author

Schetelig, Johannes, primary, Baldauf, Henning, additional, Heidenreich, Falk, additional, Hoogenboom, Jorinde D., additional, Spellman, Stephen R., additional, Kulagin, Alexander, additional, Schroeder, Thomas, additional, Sengeloev, Henrik, additional, Dreger, Peter, additional, Forcade, Edouard, additional, Vydra, Jan, additional, Wagner-Drouet, Eva Maria, additional, Choi, Goda, additional, Paneesha, Shankara, additional, Miranda, Nuno A. A., additional, Tanase, Alina, additional, de Wreede, Liesbeth C., additional, Lange, Vinzenz, additional, Schmidt, Alexander H., additional, Sauter, Jürgen, additional, Fein, Joshua A., additional, Bolon, Yung-Tsi, additional, He, Meilun, additional, Marsh, Steven G. E., additional, Gadalla, Shahinaz M., additional, Paczesny, Sophie, additional, Ruggeri, Annalisa, additional, Chabannon, Christian, additional, and Fleischhauer, Katharina, additional

Published
2024
Full Text
View/download PDF

40. Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018

Author

Valcarcel, Bryan, Schonfeld, Sara J., Meyer, Christa L., Brunson, Ann, Cooley, Julianne J.P., Abrahão, Renata, Wun, Ted, Auletta, Jeffery J., Gadalla, Shahinaz M., Engels, Eric, Albert, Paul S., Spellman, Stephen R., Rizzo, J. Douglas, Shaw, Bronwen E., Muffly, Lori, Keegan, Theresa H.M., and Morton, Lindsay M.

Published
2024
Full Text
View/download PDF

41. Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation

Author

Hahn, Theresa, Wang, Junke, Preus, Leah M., Karaesmen, Ezgi, Rizvi, Abbas, Clay-Gilmour, Alyssa I., Zhu, Qianqian, Wang, Yiwen, Yan, Li, Liu, Song, Stram, Daniel O., Pooler, Loreall, Sheng, Xin, Haiman, Christopher A., Berg, David Van Den, Webb, Amy, Brock, Guy, Spellman, Stephen R., Onel, Kenan, McCarthy, Philip L., Pasquini, Marcelo C., and Sucheston-Campbell, Lara E.

Published
2021
Full Text
View/download PDF

42. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

Author

Lee, Catherine J., Wang, Tao, Chen, Karen, Arora, Mukta, Brazauskas, Ruta, Spellman, Stephen R., Kitko, Carrie, MacMillan, Margaret L., Pidala, Joseph A., Badawy, Sherif M., Bhatt, Neel, Bhatt, Vijaya R., DeFilipp, Zachariah, Diaz, Miguel A., Farhadfar, Nosha, Gadalla, Shahinaz, Hashmi, Shahrukh, Hematti, Peiman, Hossain, Nasheed M., Inamoto, Yoshihiro, Lekakis, Lazaros J., Sharma, Akshay, Solomon, Scott, Lee, Stephanie J., and Couriel, Daniel R.

Published
2024
Full Text
View/download PDF

43. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic

Author

Hsu, Jack W., Farhadfar, Nosha, Murthy, Hemant, Logan, Brent R., Bo-Subait, Stephanie, Frey, Noelle, Goldstein, Steven C., Horowitz, Mary M., Lazarus, Hillard, Schwanke, Joshua D., Shah, Nirali N., Spellman, Stephen R., Switzer, Galen E., Devine, Steven M., Shaw, Bronwen E., and Wingard, John R.

Published
2021
Full Text
View/download PDF

44. Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post–unrelated HCT

Author

Wang, Yiwen, Zhou, Weiyin, Wang, Junke, Karaesmen, Ezgi, Tang, Hancong, McCarthy, Philip L., Pasquini, Marcelo C., Wang, Youjin, McReynolds, Lisa J., Katki, Hormuzd A., Machiela, Mitchell J., Yeager, Meredith, Pooler, Loreall, Sheng, Xin, Haiman, Christopher A., Van Den Berg, David, Spellman, Stephen R., Wang, Tao, Kuxhausen, Michelle, Chanock, Stephen J., Lee, Stephanie J., Clay-Gilmour, Alyssa I., Hahn, Theresa E., Gadalla, Shahinaz M., and Sucheston-Campbell, Lara E.

Published
2021
Full Text
View/download PDF

45. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Author

Dillon, Laura W., Gui, Gege, Ravindra, Niveditha, Andrew, Georgia, Mukherjee, Devdeep, Wong, Zoë C., Huang, Ying, Gerhold, Jason, Holman, Matt, D'Angelo, Julian, Miller, Jeffrey, Higgins, Jake, Salk, Jesse J., Auletta, Jeffrey J., El Chaer, Firas, Devine, Steven M., Jimenez Jimenez, Antonio Martin, De Lima, Marcos J. G., Litzow, Mark R., Kebriaei, Partow, Saber, Wael, Spellman, Stephen R., Zeger, Scott L., Page, Kristin M., Hourigan, Christopher S., Dillon, Laura W., Gui, Gege, Ravindra, Niveditha, Andrew, Georgia, Mukherjee, Devdeep, Wong, Zoë C., Huang, Ying, Gerhold, Jason, Holman, Matt, D'Angelo, Julian, Miller, Jeffrey, Higgins, Jake, Salk, Jesse J., Auletta, Jeffrey J., El Chaer, Firas, Devine, Steven M., Jimenez Jimenez, Antonio Martin, De Lima, Marcos J. G., Litzow, Mark R., Kebriaei, Partow, Saber, Wael, Spellman, Stephen R., Zeger, Scott L., Page, Kristin M., and Hourigan, Christopher S.

Abstract

Importance: Persistence of FLT3 internal tandem duplication (ITD) in adults with acute myeloid leukemia (AML) in first complete remission (CR) prior to allogeneic hematopoietic cell transplant (HCT) is associated with increased relapse and death after transplant, but the association between the level of measurable residual disease (MRD) detected and clinical outcome is unknown. Objective: To examine the association between pre–allogeneic HCT MRD level with relapse and death posttransplant in adults with AML in first CR. Design, Setting, and Participants: In this cohort study, DNA sequencing was performed on first CR blood from patients with FLT3-ITD AML transplanted from March 2013 to February 2019. Clinical follow-up was through May 2022. Data were analyzed from October 2022 to December 2023. Exposure: Centralized DNA sequencing for FLT3-ITD in pre–allogeneic HCT first CR blood using a commercially available kit. Main Outcomes and Measures: The primary outcomes were overall survival and cumulative incidence of relapse, with non–relapse-associated mortality as a competing risk post–allogeneic HCT. Kaplan-Meier estimations (log-rank tests), Cox proportional hazards models, and Fine-Gray models were used to estimate the end points. Results: Of 537 included patients with FLT3-ITD AML from the Pre-MEASURE study, 296 (55.1%) were female, and the median (IQR) age was 55.6 (42.9-64.1) years. Using the variant allele fraction (VAF) threshold of 0.01% or greater for MRD positivity, the results closely aligned with those previously reported. With no VAF threshold applied (VAF greater than 0%), 263 FLT3-ITD variants (median [range] VAF, 0.005% [0.0002%-44%]), and 177 patients (33.0%) with positive findings were identified. Multivariable analyses showed that residual FLT3-ITD was the variable most associated with relapse and overall survival, with a dose-dependent correlation. Patients receiving reduced-intensity conditioning without melphalan or nonmyeloablative conditioning h

Published
2024

48. The health risk of social disadvantage is transplantable into a new host.

Author

Turcotte, Lucie M., Tao Wang, Beyer, Kirsten M., Cole, Steven W., Spellman, Stephen R., Allbee-Johnson, Mariam, Williams, Eric, Yuhong Zhou, Verneris, Michael R., Rizzo, J. Douglas, and Knight, Jennifer M.

Subjects
HEMATOPOIETIC stem cell transplantation, SOCIOECONOMIC disparities in health, SOCIAL determinants of health, HEALTH equity, MORTALITY risk factors
Abstract

Low socioeconomic status (SES) is a risk factor for mortality and immune dysfunction across a wide range of diseases, including cancer. However, cancer is distinct in the use of allogeneic hematopoietic cell transplantation (HCT) as a treatment for hematologic malignancies to transfer healthy hematopoietic cells from one person to another. This raises the question of whether social disadvantage of an HCT cell donor, as assessed by low SES, might impact the subsequent health outcomes of the HCT recipient. To evaluate the cellular transplantability of SES-associated health risk, we analyzed the health outcomes of 2,005 HCT recipients who were transplanted for hematologic malignancy at 125 United States transplant centers and tested whether their outcomes differed as a function of their cell donor's SES (controlling for other known HCT-related risk factors). Recipients transplanted with cells from donors in the lowest quartile of SES experienced a 9.7% reduction in overall survival (P = 0.001) and 6.6% increase in treatment-related mortality within 3 y (P = 0.008) compared to those transplanted from donors in the highest SES quartile. These results are consistent with previous research linking socioeconomic disadvantage to altered immune cell function and hematopoiesis, and they reveal an unanticipated persistence of those effects after cells are transferred into a new host environment. These SES-related disparities in health outcomes underscore the need to map the biological mechanisms involved in the social determinants of health and develop interventions to block those effects and enhance the health of both HCT donors and recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study

Author

Gadalla, Shahinaz M, Wang, Youjin, Wang, Tao, Onabajo, Olusegun O, Banday, A Rouf, Obajemu, Adeola, Karaesman, Ezgi, Sucheston-Campbell, Lara, Hahn, Theresa, Sees, Jennifer A, Spellman, Stephen R, Lee, Stephanie J, Katki, Hormuzd A, and Prokunina-Olsson, Ludmila

Published
2020
Full Text
View/download PDF

50. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Author

D'Souza, Anita, Fretham, Caitrin, Lee, Stephanie J, Arora, Mukta, Brunner, Janet, Chhabra, Saurabh, Devine, Steven, Eapen, Mary, Hamadani, Mehdi, Hari, Parameswaran, Pasquini, Marcelo C, Perez, Waleska, Phelan, Rachel A, Riches, Marcie L, Rizzo, J Douglas, Saber, Wael, Shaw, Bronwen E, Spellman, Stephen R, Steinert, Patricia, Weisdorf, Daniel J, and Horowitz, Mary M

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results